Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Patients with alopecia areata who did not respond to initial treatment with a JAKi or who did not maintain response may ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tyrosine kinase inhibitors (TKIs) are emerging as a ...
Zongertinib gained accelerated approval for unresectable/metastatic HER2 kinase-domain–mutant nonsquamous NSCLC, with 76% ORR and DOR ≥12 months in 44%. AMPLIFY ...
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and ...
Please provide your email address to receive an email when new articles are posted on . In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially ...
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical ...
Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results